BMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bristol-Myers Squibb Co (BMY) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has a solid dividend yield and promising pipeline catalysts, the technical indicators are neutral, insider selling is significant, and the options data suggests bearish sentiment. The investor may consider holding off on buying until there are clearer positive signals or a more favorable entry point.
The MACD is negative and contracting, indicating weak momentum. RSI is neutral at 59.086, and moving averages are converging, showing no clear trend. Key resistance levels are at 60.289 and 61.317, while support levels are at 56.962 and 55.934. The stock is trading near its pivot point of 58.626, suggesting limited immediate upside.
Strong dividend yield of 4.4%, significantly higher than the S&P 500 average.
Promising pipeline catalysts, including Phase III Milvexian SSP and AFib data expected in H2
Revenue growth in Q4 2025 (up 1.3% YoY) and significant improvement in net income (up 1409.72% YoY).
Significant insider selling, with a 15753.10% increase in the last month.
Challenges from patent expirations on key drugs like Eliquis and Opdivo, which may pressure future revenue and dividend sustainability.
Neutral hedge fund activity and no significant trading trends.
Analysts express concerns about macroeconomic uncertainties and the company's ability to sustain growth.
In Q4 2025, revenue increased by 1.3% YoY to $12.5 billion. Net income surged by 1409.72% YoY to $1.087 billion, driven by operational improvements. EPS rose by 1225% YoY to $0.53, and gross margin improved to 65.34%, up 8.43% YoY. The company projects 2026 annual revenue between $46 billion and $47.5 billion, with free cash flow exceeding dividend needs.
Analyst sentiment is mixed. Recent ratings include multiple Buy ratings with price targets ranging from $60 to $75, citing pipeline potential and dividend attractiveness. However, some analysts maintain Hold or Underweight ratings, highlighting risks from patent expirations and macroeconomic uncertainties.
